Dara Biosciences Inc (DARA) financial statements (2021 and earlier)

Company profile

Business Address 8601 SIX FORKS ROAD SUITE 160
RALEIGH, NC 27615
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments57101214167
Cash and cash equivalents57101214167
Receivables1111000
Inventory, net of allowances, customer advances and progress billings0000000
Inventory0000000
Other undisclosed current assets0000000
Total current assets:68111415178
Noncurrent Assets
Property, plant and equipment0000000
Intangible assets, net (including goodwill)3444444
Goodwill1111111
Intangible assets, net (excluding goodwill)3333333
Restricted cash and investments0000000
Total noncurrent assets:3444444
TOTAL ASSETS:10121518192011
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3222222
Accounts payable1110111
Accrued liabilities1111001
Employee-related liabilities1111110
Debt0000000
Other undisclosed current liabilities0111000
Total current liabilities:3344222
Noncurrent Liabilities
Long-term debt and lease obligation0000000
Capital lease obligations0000000
Liabilities, other than long-term debt0000000
Deferred revenue and credits0000000
Other undisclosed noncurrent liabilities    111
Total noncurrent liabilities:0000111
Total liabilities:4344333
Stockholders' equity
Stockholders' equity attributable to parent, including:691114171710
Common stock0000000
Additional paid in capital80808080818169
Accumulated deficit(75)(72)(69)(66)(64)(62)(60)
Other undisclosed stockholders' equity attributable to parent00000(1)0
Stockholders' equity attributable to noncontrolling interest    (1)(1)(1)
Other undisclosed stockholders' equity     2 
Total stockholders' equity:69111415199
Other undisclosed liabilities and equity     (1) 
TOTAL LIABILITIES AND EQUITY:10121518192011

Income statement (P&L) ($ in millions)

9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
Revenues1111100
Cost of revenue
(Cost of Goods and Services Sold)
(0)(0)(0)(0)(0)(0)(0)
Gross profit:1100000
Operating expenses(4)(4)(4)(2)(3)(3)(3)
Other undisclosed operating income0000000
Operating loss:(3)(3)(3)(2)(2)(3)(3)
Nonoperating income (expense)(0)0(0)(0)(0)(0)0
Other nonoperating income      0
Interest and debt expense      (0)
Loss from continuing operations before equity method investments, income taxes:(3)(3)(3)(2)(2)(3)(3)
Other undisclosed income from continuing operations before income taxes      0
Net loss:(3)(3)(3)(2)(2)(3)(3)
Net income attributable to noncontrolling interest   0000
Net loss available to common stockholders, diluted:(3)(3)(3)(2)(2)(3)(3)

Comprehensive Income ($ in millions)

9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
Net loss:(3)(3)(3)(2)(2)(3)(3)
Comprehensive loss:(3)(3)(3)(2)(2)(3)(3)
Comprehensive income, net of tax, attributable to noncontrolling interest   0000
Comprehensive loss, net of tax, attributable to parent:(3)(3)(3)(2)(2)(3)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: